You are here

AstraZeneca

ACC: AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes

ACC: AstraZeneca's Farxiga chops follow-up CV events by 16% in heart attack patients with diabetes

Fierce Pharma

American College of Cardiology

Flag link:

3 Top Diabetes Stocks to Watch in March

3 Top Diabetes Stocks to Watch in March

Yahoo/Motley Fool

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Yahoo/Benzinga

SAGE Therapeutics

Ligand Pharmaceuticals

Jazz Pharmaceuticals

Lexicon Pharmaceuticals

Leap Therapeutics

Flag link:

ExcepGen emerges from Y Combinator, taking aim at better proteins for drug discovery

ExcepGen emerges from Y Combinator, taking aim at better proteins for drug discovery

Fierce Biotech

Flag link:

AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres

AstraZeneca lines up a $20M installment plan to launch a new oncology collaboration with microbiome player Seres

Endpoints

Seres Therapeutics

Flag link:

Was AstraZeneca CEO Pascal Soriot happy with his $14.8M in '18 compensation? Probably not so much

Was AstraZeneca CEO Pascal Soriot happy with his $14.8M in '18 compensation? Probably not so much

Endpoints

Flag link:

AstraZeneca gets FDA expanded approval for Farxiga and Xigduo XR

AstraZeneca gets FDA expanded approval for Farxiga and Xigduo XR

Pharmaceutical Business Review

type 2 diabetes

Flag link:

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

AstraZeneca, Merck notch another major Lynparza trial win — this time in pancreatic cancer

Endpoints

pancreatic cancer

clinical trials

BRCA-mutated prostate cancer

Flag link:

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study

Endpoints

clinical trials

Flag link:

The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress

The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress

Stat

Richard Gonzalez

Jennifer Taubert

Olivier Brandicourt

Giovanni Caforio

Bristol-Myers Squibb

Flag link:

2 Pharma Stocks in the Middle of an Oncology Sales Explosion

2 Pharma Stocks in the Middle of an Oncology Sales Explosion

Motley Fool

Flag link:

AZ’s CEO dismisses “fake news” about his imminent departure

AZ’s CEO dismisses “fake news” about his imminent departure

Pharmaforum

Flag link:

AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales

AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales

Yahoo/Zacks.com

Flag link:

AstraZeneca sweeps away the MedImmune name as CEO Soriot restructures R&D

AstraZeneca sweeps away the MedImmune name as CEO Soriot restructures R&D

Endpoints

Flag link:

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

BioSpace

Flag link:

Powerful Senate committee invites pharma executives to testify

Powerful Senate committee invites pharma executives to testify

Reuters

Bristol-Myers Squibb

Flag link:

AZ’s lung drug gets fast development in EU and US

AZ’s lung drug gets fast development in EU and US

Pharmaforum

Flag link:

AstraZeneca’s Forxiga recommended for marketing authorization in EU

AstraZeneca’s Forxiga recommended for marketing authorization in EU

Pharmaceutical Business Review

type 1 diabetes

Flag link:

AstraZeneca and UPMC Health Plan Form Unique Outcome Based Agreement

AstraZeneca and UPMC Health Plan Form Unique Outcome Based Agreement

CP Wire

outcomes-based contracts

Flag link:

AstraZeneca and UPMC Health Plan Form Unique Outcome Based Agreement

Flag link:

Pages